Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Halozyme Therapeutics, Inc.    HALO

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Halozyme Therapeutics, Inc. : Halozyme to Host First Quarter 2012 Financial Results Conference Call

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/30/2012 | 10:20pm CEST

SAN DIEGO, April 30, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2012 on Monday, May 7, 2012 at 4:30 p.m. ET/1:30 p.m. PT. Gregory I. Frost, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the first quarter 2012.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The call will be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to www.halozyme.com approximately fifteen minutes prior to the call to register, download, and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (877) 407-8037 (domestic callers) or (201) 689-8037 (international callers). A telephone replay will be available shortly after the call by dialing (877) 660-6853 (domestic callers) or (201) 612-7415 (international callers) using account number 367 and replay ID number 393124.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets HYLENEX® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Media/Investor Contact:
Anne Erickson
Executive Director
Halozyme Therapeutics
858-704-8264
aerickson@halozyme.com

SOURCE Halozyme Therapeutics, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on HALOZYME THERAPEUTICS, INC
03/29 HALOZYME THERAPEUTICS : FDA Advisory Committee Provides Unanimous Recommendation..
03/03 Abzena Says Partner To Report Data At Cancer Association Meeting
03/01 HALOZYME THERAPEUTICS INC : Results of Operations and Financial Condition (form ..
03/01 HALOZYME THERAPEUTICS : Management's Discussion and Analysis of Financial Condit..
02/28 HALOZYME THERAPEUTICS : Reports Fourth Quarter And Full Year 2016 Financial Resu..
02/28 HALOZYME THERAPEUTICS : reports 4Q loss
02/24 MABVAX THERAPEUTICS : Studies Lead Investigational Drug MVT-5873 with Halozyme P..
02/23 HALOZYME THERAPEUTICS : To Present At Upcoming Healthcare Conferences
02/13 MABVAX THERAPEUTICS : Studies Lead Investigational Drug MVT-5873 with Halozyme P..
02/01 HALOZYME THERAPEUTICS : To Host Fourth Quarter 2016 Financial Results Conference..
More news
Sector news : Bio Therapeutic Drugs
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
03/29 FDA Ad Comm backs subcutaneous administration of Roche's cancer med Rituxan
03/22 HALOZYME : Exploring The Potential Of PEGPH20
03/22 Best Price-Positioned Integrated Oil & Gas Stocks, As Seen By Market-Makers
03/08 Halozyme Therapeutics (HALO) Presents At Cowen and Company 37th Annual Health..
02/28 Halozyme Therapeutics' (HALO) CEO Helen Torley on Q4 2016 Results - Earnings ..